Slide 1: Quarter End Results
Quarter End Results Period Ended March 31, 2024
Slide 2: Forward looking statement
Forward looking This presentation contains forward looking statements. The words “believe”, “expect”, development, uncertainties related to the outcome of clinical trials, slower than expected statement “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. ra
Slide 3: Strategic Partnerships, Collaborations, and Licensing Agreements
As part of Genmab’s Q1 2024 Results presentation, we will discuss Strategic several products developed in collaboration with strategic partners or that Partnerships, are the result of product or technology licenses with other companies. This slide is an acknowledgement of those relationships. Collab
Slide 4: Driving Towards Our 2030 Vision
Driving Towards Our 2030 Vision Well Positioned for Growth: Solid Track Record and Financial Foundation 44 Cumulative INDs since 1999 Innovative clinical pipeline: 10 Genmab owned ≥50% 8 approved medicines based on Genmab’s innovation and antibody expertise Two approved medicines co-develope
Slide 5: Proposed Acquisition of ProfoundBio: Enhancing Genmab's Long-term Growth Profile
Proposed Acquisition of ProfoundBio: Enhancing Genmab’s Long-term Growth Profile Evolving as a Fully Proposed Acquisition of ProfoundBio Integrated Biotech Innovation Powerhouse Aligned with Genmab’s core vision & strategy Complementary to Genmab’s mid- to late-stage clinical pipeline Attractive med
Slide 6: Driving Towards Our 2030 Vision: Recent Company Events
Driving Towards Our 2030 Vision: Recent Company Events • EPKINLY/TEPKINLY (epcoritamab) • Multiple data presentations across programs – Additional regulatory approvals / submissions • Acasunlimab (GEN1046/BNT311) – New Phase 3 trial previously untreated FL – Phase 2 second-line NSCLC data to be pres
Slide 7: Select Royalty Medicines Portfolio Performance
Select Royalty Medicines Portfolio Performance Net sales Q1 YoY DARZALEX • Leader across lines of therapy; 1L share gains driven by long $2,692M 19% term OS data • PERSEUS filed in transplant eligible MM incl maintenance Kesimpta $637M 66% • Strong US & ex-US growth driven by increased demand and st
Slide 8: Genmab Commercialized Medicines Performance Summary
Genmab Commercialized Medicines Performance Summary Net sales (USD) Q1 YoY Q1 YoY $54M ** $27M 42% The CORE Therapy across B-cell Malignancies Clear answer in 2L+ cervical cancer • Strong early launch performance in US, asserting • Strong account activation continued from Q4 driving in-class market
Slide 9: Q1 2024: Driving Towards Our 2030 Vision
Q1 2024: Driving Towards Our 2030 Vision EPKINLY/TEPKINLY Regulatory Approvals & Launches 42% increase in recurring revenues Focused Investment: expanding and accelerating our differentiated pipeline and our capabilities Team and capabilities in place for continued success © Genmab 2024 9 For Invest
Slide 10: Royalties and Net Product Sales & Collaboration Revenue Drive 46% YoY Total Revenue Growth
Royalties and Net Product Sales & Collaboration Revenue* Drive 46% YoY Total Revenue Growth Revenue, DKK Millions +46% 4,143 42% Recurring Revenue growth from Royalties 623 and Net Product Sales & Collaboration Revenue 416 Higher DARZALEX Royalties from 19% YoY Net 2,834 Sales growth 359 67 DKK
Slide 11: Focused Investments in Pipeline and Capabilities
Focused Investments in Pipeline and Capabilities Operating Expenses, DKK Millions 3,157 Operating Expense growth of 31% (38) 187 591 2,417 Securing EPKINLY launch, including building out our 2 key markets – United States and Japan Advancing Portfolio Expanding development programs – EPKINLY, Tivda
Slide 12: Condensed Income Statement: Three Months Ended March 31
Condensed Income Statement: Three Months Ended March 31 2024 2023 2024 2023 DKKM Change USDM * Total Revenue 4,143 2,834 1,309 601 411 Royalties 3,104 2,408 696 450 349 Net Product Sales/Collab oration Revenue** 416 67 349 60 10 Milestone and Reimb ursement 623 359 264 91 52 Gross Profit*** 3,958 2,
Slide 13: Robust Financial Framework
Robust Financial Framework Recurring Revenue Growth Focused Investment 8 approved products generating significant and growing Accelerating & expanding development of epcoritamab revenues - Multiple Phase 3 and other studies to start - Investing in EPKINLY launch in U.S. and Japan Genmab produc
Slide 14: 2024 Guidance: Recurring Revenue Growth and Focused Investments
2024 Guidance: Recurring Revenue Growth and Focused Investments 2024 Key Figures (DKKM) 2024 Guidance Guidance Solid Q1: on track to meet current 2024 guidance excluding Mid - Point ProfoundBio acquisition impact and related deal costs Revenue 18,700 – 20,500 19,600 Double digit revenue growth of ~1
Slide 15: Summary
Summary Clear path to reach our 2030 Vision Growing recurring revenue streams and significant underlying profitability Focused and disciplined investment approach Significant growth opportunities supported by our capital allocation strategy © Genmab 2024 15 For Investor audience only. Not fo
Slide 16: 2024 Priorities: Further Advancing Our Differentiated Product Pipeline Towards The Market
Further Advancing Our Differentiated 2024 Priorities: Product Pipeline Towards The Market Invest in Our People, Culture & Society Further scale organization aligned with differentiated Bring Our Own Medicines to Patients & Build World-class Differentiated antibody product portfolio Expand Our Market
Slide 17: Q&A Upcoming Investor Events
Q&A Upcoming Investor Events • ASCO Annual Meeting, May 31-June 4, 2024 • William Blair Healthcare Conference, June 4, 2024 • Jefferies Global Healthcare Conference, June 5, 2024 • Goldman Sachs Annual Conference, June 10-13, 2024 • Citibank Healthcare Conference, June 19, 2024 • J.P. Morgan Healthc